share_log

Help Therapeutics Completes Series C Financing of 25 Million Dollars

Help Therapeutics Completes Series C Financing of 25 Million Dollars

幫助治療公司完成2500萬美元的C系列融資
PR Newswire ·  2021/11/29 16:36

NANJING, China, Nov. 29, 2021 /PRNewswire/ -- Recently, the iPSC therapeutics leading global platform company - Help Therapeutics announced the completion of Series C financing of 25 millions of dollars. This round of financing was led by Ming Bioventures, followed by Share Capital, Beisen Medical Fund, and Jolmo Capital, with additional support from our old shareholder Purple Bull Startups, and Hoyue Capital acting as the exclusive financial advisor for this round of financing. The financing will help the company conduct and complete clinical trials of its fully independent intellectual property development pipeline, iPSC heart cell injection, and will initiate clinical studies of immune cell therapy based on iPSC technology within the next year.

南京,中國,2021年11月29日/美通社/--近日,全球領先的IPSC治療平臺公司-幫助治療學 宣佈完成C系列融資2500萬美元。本輪融資由明生物創投領投,股份資本、北森醫療基金、Jolmo Capital緊隨其後,老股東紫牛創業公司額外支持,和悦資本擔任本輪融資的獨家財務顧問。這筆融資將幫助該公司進行並完成其完全獨立的知識產權開發管道的臨牀試驗,IPSC心肌細胞注射,並將在明年內啟動基於IPSC技術的免疫細胞療法的臨牀研究。

Help Therapeutics

幫助治療學

As the first company in China to develop and manufacture cell therapy using induced pluripotent stem cell (iPSC) technology, Help Therapeutics insists on focusing on the fields of heart failure and tumor immune diseases to develop general-purpose cell therapy products to meet clinical demand.

作為中國第一家利用誘導多能幹細胞(IPSC)技術開發和製造細胞療法的公司,幫助治療學堅持聚焦心力衰竭和腫瘤免疫疾病領域,開發滿足臨牀需求的通用細胞治療產品。

The company's founder, Dr. Wang Jiaxian, is a medical doctor from the University of Hong Kong and a postdoctoral fellow at Mount Sinai School of Medicine in the United States. During his time as a cardiologist, Dr. Wang became concerned that the population of heart failure patients in China has reached over 10 million, and there are about 3 million patients with severe heart failure waiting for heart transplants every year, but only about 600 people can find heart donor, a huge gap that has become a problem for the entire medical community. Dr. Wang chose to enter the field of iPSC cell therapy in 2010, convinced that iPSC technology is a groundbreaking technology for human medicine, and looking forward to saving heart failure patients through this innovative cutting-edge technology. After years of development, the company has developed several product pipelines based on iPSC technology, mastering advanced iPSC reprogramming technology while having the capability of large-scale automated production and cell quality inspection of iPSC drugs.

該公司創始人王家賢博士是香港大學的醫學博士,也是#年西奈山醫學院的博士後研究員。美國。在擔任心臟病專家期間,王醫生開始擔心,中國的心力衰竭患者已經超過1000萬,每年大約有300萬嚴重心力衰竭患者等待心臟移植,但只有大約600人能找到心臟捐贈者,這一巨大的缺口已經成為整個醫學界的一個問題。王博士於2010年選擇進入IPSC細胞治療領域,深信IPSC技術是人類醫學的一項突破性技術,並期待通過這一創新前沿技術拯救心力衰竭患者。經過多年的發展,公司開發了多條基於IPSC技術的產品流水線,掌握了先進的IPSC重編程技術,同時具備了IPSC藥品的大規模自動化生產和細胞質量檢測能力。

iPSC pipeline layout  Break through the heart failure treatment dilemma

IPSC管道佈局突破心力衰竭治療困局

Help Therapeutics has laid out several R&D pipelines in the areas of heart failure and tumor immunity, among which iPSC technology therapy for the treatment of moderate to severe heart failure has entered several authoritative centers nationwide to conduct large-scale randomized controlled human clinical trials. Help Therapeutics has accumulated profound experience in the field of heart failure cell therapy: In 2020, Nature reported the world's first human study of iPSC cells for end-stage heart failure conducted jointly by the company and Nanjing Drum Tower Hospital. Based on 24-month follow-up data from three patients in this clinical trial, the efficacy and safety of Help Therapeutics's iPSC-derived cardiomyocyte drug for the treatment of severe heart failure were excellent.

幫助治療學在心力衰竭和腫瘤免疫領域佈局了多條研發流水線,其中治療中重度心力衰竭的IPSC技術療法已進入全國多個權威中心進行大規模隨機對照人體臨牀試驗。Help Treateutics在心力衰竭細胞治療領域積累了深厚的經驗:2020年,自然界據報道,該公司和南京鼓樓醫院聯合進行了世界上第一項針對IPSC細胞治療終末期心力衰竭的人體研究。根據這項臨牀試驗中三名患者24個月的隨訪數據,Help Treateutics公司的IPSC衍生心肌細胞藥物治療嚴重心力衰竭的療效和安全性都非常好。

The company has already obtained the first iPSC technology-based heart failure cell therapy clinical study filing from the National Health Care Commission in China, and is also actively preparing clinical registration filings for both the U.S. and China for its heart failure treatment pipeline. After clinical trials, this product is expected to be the first iPSC cell therapy drug for moderate to severe heart failure in China and the world, and its social and commercial value will be incalculable.

該公司已經獲得了中國國家衞生保健委員會提交的第一份基於IPSC技術的心力衰竭細胞療法臨牀研究文件,並正在積極準備美國和美國的臨牀註冊文件。中國因為它的心力衰竭治療管道。經過臨牀試驗,該產品有望成為中國乃至全球首個治療中重度心力衰竭的IPSC細胞治療藥物,其社會和商業價值將不可估量。

Artificial intelligence fully automated production line, the world's first biopharmaceutical 4.0 era

人工智能全自動生產線vt.的.世界上第一個生物製藥4.0時代

With the development of the cell therapy industry, the quantity and quality of cell culture are in more refined and higher demand, both from the perspective of clinical demand and R&D exploration. The current manual culture of cell therapy products has long operation time, large variation between product batches, low batch culture capacity and other industry bottlenecks, and thus the cost and terminal selling price of cellular drugs remain high, and cannot really reach the majority of patients. Therefore, addressing the commercial mass production of cells has become central to the development of cell therapy companies.

隨着細胞治療行業的發展,無論是臨牀需求還是研發探索,對細胞培養的數量和質量都提出了更高、更精細的要求。目前的細胞治療產品人工培養存在操作時間長、產品批次差異大、批次培養能力低等行業瓶頸,細胞藥物的成本和終端銷售價格居高不下,無法真正惠及廣大患者。因此,解決細胞的商業化大規模生產已經成為細胞治療公司發展的核心。

Help Therapeutics is at the forefront of the world's technology in terms of cell mass production and quality assurance. Its fully automated production line has reached the international leading position, improving the quality and stability of cellular products while significantly reducing production costs. The annual production capacity of a single production line can meet 100,000 doses, contributing to the popularization of cellular products. The company's fully automated production pipeline was selected for the National "13th Five-Year Plan" Science and Technology Innovation Achievement Exhibition.

幫助治療學在細胞批量生產和質量保證方面處於世界技術的前沿。其全自動化生產線已達到國際領先地位,在大幅降低生產成本的同時,提高了蜂窩產品的質量和穩定性。單條生產線的年產能可達十萬劑,為蜂窩產品的普及做出貢獻。該公司的全自動化生產流水線入選國家“十三五”科技創新成果展。

Taking the responsibility of the country as our own

以國家之責為己任

Help Therapeutics has the first induced pluripotent stem cell (iPSC) biospecimen bank authorized by the Ministry of Science and Technology for the preservation of human genetic resources in China. Entrusted by the National Human Genetic Resources Sharing Service Platform and as the only officially recognized iPSC rare disease cell bank in the National 14th Five-Year Plan (National Science and Technology Heritage Office [2021]-BC0022), Help Therapeutics carries the heavy responsibility of human genetic material and makes every effort to promote the role of China's iPSC technology platform and rare disease research and development treatment. Help Therapeutics will provide high-quality and diversified biological samples to research institutions and enterprises, accelerate rare disease research and orphan drug development, and help the rapid development of iPSC cell industry.

幫助治療學擁有國家科技部批准的我國第一個人工誘導多能幹細胞(IPSC)生物樣本庫,用於保存人類遺傳資源。受國家人類遺傳資源共享服務平臺委託,作為國家十四五規劃(國家科技遺產辦)唯一官方認可的IPSC罕見病細胞庫[2021]--BC0022),Help Treeutics肩負着人類遺傳物質的重任,全力推動中國IPSC技術平臺和罕見病研發治療。Help Treeutics將為研究機構和企業提供優質、多樣化的生物樣本,加速罕見病研究和孤兒藥物開發,助力IPSC細胞產業快速發展。

SOURCE Help Therapeutics

信源幫助治療公司(Source Help Treeutics)

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論